Background
==========

It has long been recognized that psychiatric disorders and symptoms aggregate in families and the evidence for a substantial role for genetic factors is incontrovertible \[[@B1]\]. Genetic epidemiological studies of autism, bipolar disorder and schizophrenia show that the risk of developing one of these specific psychiatric illnesses is proportional to the amount of genetic material shared with an affected individual \[[@B1]\]. Heritability has been estimated as being at least 80% for all these disorders \[[@B2]-[@B4]\], which, to put it in context, is equivalent to that for type I diabetes (about 80%) \[[@B5]\] but greater than that for breast cancer \[[@B6]\] or Parkinson\'s disease \[[@B7]\].

The majority of psychiatric disorders, like other common conditions, are genetically complex. In psychiatry, genetic complexity has been compounded by phenotypic complexity. Psychiatric diagnosis cannot be made on the basis of biological investigation or validated against a common pathogenesis. Psychiatric \'disorders\' such as autism, schizophrenia and bipolar disorder are therefore effectively groups of symptoms making up syndromes that define groups of patients who show broadly similar outcomes and who respond similarly to treatment. Such diagnostic categories are therefore likely to be heterogeneous and the boundaries between them somewhat arbitrary.

Autism, schizophrenia and bipolar disorder have traditionally been considered as separate disease entities, although they do share some common behavioral characteristics and cognitive deficits. The distinction between schizophrenia and bipolar disorder has been justified for many years by reference to family studies showing that these disorders seem to \'breed true\'. However, this view has been challenged \[[@B8]\], and a recent large-scale study has shown that relatives of individuals affected with schizophrenia have increased risks of bipolar disorder, and vice versa \[[@B9]\]. Definitive genetic epidemiological studies of the genetic relationship between autism and these disorders are lacking, although there is some evidence for shared genetic factors \[[@B10]\]. In recent years new molecular genetic findings, particularly from the application of genome-wide association studies (GWASs) and other genomic technologies \[[@B11]-[@B14]\], have implicated risk factors for these disorders, and this has allowed the possibility of a genetic relationship between them to be explored directly and current orthodoxies to be challenged \[[@B8]-[@B10]\].

Copy number variant and rare allele studies
===========================================

Autism spectrum disorders (ASDs) such as autism, Asperger\'s syndrome and Rett\'s syndrome, are developmental psychiatric disorders with high heritability \[[@B15]\]. Over the past few years, genetic studies of ASDs have consistently identified rare and *de novo*point mutations and large structural variants present in genes encoding interacting synaptic proteins \[[@B16]\]. Such studies have reported co-segregation of putative high-risk alleles (such as deletions or point mutations) with ASDs or performed so-called \'burden analysis\', in which different alleles of a particular gene are aggregated and the frequency in cases compared with that in controls. Initial studies of ASDs using small samples found rare missense point and structural mutations (such as copy number variants, CNVs) in the X-linked Neuroligin-3 and Neuroligin-4 (*NLGN4*) genes \[[@B17]-[@B19]\]. Neuroligins are a family of post-synaptic proteins that bind trans-synaptically to a family of pre-synaptic proteins called neurexins. Although these findings were interesting, incomplete penetrance of the mutations and lack of power made the results equivocal. However, missense mutations were subsequently identified in the Neurexin-1 (*NRXN1*) gene at a high frequency in individuals with autism \[[@B20]\]. These suggestive findings have been augmented by the results of recent genomic studies discussed below.

Traditional karyotyping, GWASs and comparative genome hybridization (CGH) analyses have been used to identify large chromosomal structural losses (deletions) and gains (duplications) in individuals with ASDs \[[@B21]-[@B24]\]. A burden analysis study of approximately 200 affected individuals identified two translocation events at *NRXN1*in separate samples, one disrupting the coding sequence and the other lying 5\' to the gene \[[@B24]\]. A further study of over 1,000 pedigrees using approximately 10,000 single-nucleotide polymorphisms (SNPs) identified a 300 kb deletion of coding exons of *NRXN1*co-segregating with autism \[[@B22]\].

Genome-wide analyses have also implicated further related and interacting synaptic protein-coding genes in the etiology of ASDs. First, a study of 427 ASD cases using approximately 500,000 SNPs identified a 6 Mb *de novo*deletion encompassing *NLGN4*\[[@B23]\] and a 270 kb deletion at *SHANK3*. *SHANK3*encodes a post-synaptic protein that indirectly binds to neuroligins. Second, burden analyses revealed a high frequency of point mutations of *SHANK3*in ASD cases \[[@B25],[@B26]\]. Third, *CNTNAP2*, which encodes a member of the neurexin family that resides in the juxtaparanodal region of myelinated neurons \[[@B27]\], shows evidence for common-allele association with ASDs \[[@B28],[@B29]\] as well as an increased burden of rare protein-coding mutations \[[@B30]\] and large *de novo*deletions \[[@B31],[@B32]\].

The evidence implicating synaptic cell adhesion molecules and their related proteins in ASDs is strong. Data implicating them in schizophrenia is now arguably even stronger. A whole-genome screen for large chromosomal abnormalities using array-CGH performed in 93 individuals with schizophrenia identified a hemizygous loss at *NRXN1*in one case \[[@B33]\]. The deletion of exon 1 was also present in an affected sibling and no deletions of *NRXN1*were observed in 372 controls, suggesting that the allele may be pathogenic. The same study also found a large (1.4 Mb) *de novo*duplication event in an individual with an ASD that spanned *APBA2*; this is an intriguing result given that the gene encodes a protein (MINT2) that binds to intracellular domains of neurexins \[[@B33]\]. Further to this, an independent CGH study identified rare deletions of *NRXN1*in monozygotic twins both diagnosed with early-onset schizophrenia \[[@B34]\].

Higher-density, lower-cost genome-wide screens using GWAS technologies have made it feasible to screen many thousands of individuals for smaller copy number variations. Using over 300,000 probes across the genome assayed in approximately 3,000 European cases and 10 times as many European controls, burden analysis revealed many deletions at the *NRXN1*locus \[[@B35]\]. The authors \[[@B35]\] reported a significant excess of protein-coding deletions present in cases, a finding that is replicated in a similar analysis performed on an independent sample of approximately 3,000 cases of European descent and 3,000 controls \[[@B36]\] and also in two further studies using smaller sample sizes \[[@B37],[@B38]\]. So far, no data implicating neuroligins and shanks in schizophrenia have been reported. However, hemizygosity of the *CNTNAP2*gene, which encodes a member of the neurexin family, contactin-associated protein-like 2 (CASPR2), has been reported in schizophrenia \[[@B36],[@B39]\] and also in individuals with mental retardation \[[@B39]\].

Although the available data provide relatively strong evidence that disruption of the Neurexin-1 locus (*NRXN1*) is a risk factor for schizophrenia \[[@B40]\] and ASDs \[[@B22],[@B24]\], evidence in relation to bipolar disorder is lacking. This might reflect the relative paucity of studies addressing this hypothesis, but it could be the result of a discontinuity between bipolar disorder and schizophrenia in relation to the role of CNVs (see below).

The recent application of genome-wide technologies has shown that the burden of large, rare CNVs is increased in schizophrenia when compared with controls, and that this implicates specific loci \[[@B34],[@B36],[@B41],[@B42]\]. Studies of such magnitude have not yet been performed for ASDs, although there is evidence for the involvement of specific CNVs \[[@B43]\]. In contrast, there is evidence that the global burden of duplications or deletions in bipolar disorder is substantially less than for schizophrenia and ASDs \[[@B44],[@B45]\]. Specific deletions associated with schizophrenia include those at 22q11.2, 1q21.1 and 15q13.3, and these have also been found in association with mental retardation, autism and attention deficit hyperactivity disorder \[[@B36],[@B41],[@B46]-[@B50]\] while that at 15q13.3 has also been implicated in idiopathic generalized epilepsy \[[@B51]\]. Therefore, just as for *NRXN1*deletions, it is apparent that these large CNVs confer risk of a range of neurodevelopmental phenotypes, including autism, mental retardation and schizophrenia. However, similar evidence is lacking for bipolar disorder and there is a suggestion that CNVs might have a less prominent role in this phenotype.

Genome-wide association studies
===============================

The advent of the GWAS has allowed most of the common SNP variation in the human genome to be tested for association \[[@B52]\] and the first wave of such studies has been reported for schizophrenia \[[@B11],[@B13],[@B14],[@B38],[@B53]\], bipolar disorder \[[@B54]-[@B56]\] and autism \[[@B57]\]. Several loci have been implicated at genome-wide levels of statistical significance for schizophrenia \[[@B11],[@B13],[@B14],[@B53]\], including *ZNF804A*(encoding a protein with zinc finger and nucleic acid binding domains) \[[@B11]\] and the major histocompatibility complex (MHC) region \[[@B13],[@B14],[@B53]\]. These studies have also provided strong evidence for genetic overlap between schizophrenia and bipolar disorder \[[@B13],[@B58]\]. However, these associations implicate common alleles with small effects, and findings from GWASs do not yet clearly suggest a specific biological process. So far there have been no systematic comparisons of GWAS data for ASDs with those from schizophrenia or bipolar disorder. However, intriguing associations have been reported at voltage-gated calcium channel genes across all these phenotypes \[[@B56],[@B58]-[@B60]\]. Furthermore, there have been recent reports of association for common alleles at several GABA receptor genes in a subtype of bipolar disorder and schizophrenia \[[@B61],[@B62]\], which implicate loci also reported as associated with ASDs \[[@B23],[@B63]-[@B65]\].

A biological process disrupted across traditional diagnostic boundaries?
========================================================================

The evidence for involvement of neurexins (*NRXN1*), neuroligins (*NLGN4*) and related proteins such as shanks (*SHANK3*), MINT2 (*A2BP1*) and CASPR2 (*CNTNAP2*) in ASDs is substantial and growing. There is also strong evidence implicating some of these genes in schizophrenia, although not all of them have been examined. Given this overlap, it is possible that the genes may be exerting their effects through a biological pathway common to both disorders.

The neurexins are a family of transmembrane proteins that have extracellular, membranous and intracellular domains \[[@B16],[@B66],[@B67]\]. Neurexins can be divided into two groups, α and β neurexins; both are encoded by three genes. The neurexins are primarily expressed in neurons, where they are known as pre-synaptic heterophilic adhesion molecules, and they typically bind across the synapse to neuroligins. The neuroligins represent a similar class of proteins to neurexins and the binding of the two types of molecule to each other is controlled by alternative splicing. The intracellular domains of neurexins (and neuroligins) bind scaffolding proteins and assemble large molecular complexes that are known to link to synaptic systems such as receptors, ion channels and vesicle release machinery \[[@B16],[@B66],[@B67]\].

Neurexins are best known for their ability to promote cell adhesion and synaptogenesis when neuroligins are present on the neighboring cell \[[@B16],[@B66],[@B67]\]. Even in non-neuronal cell lines, their expression promotes the generation of synapse-like machinery, such as vesicles. It seems that neurexins and neuroligins are necessary for both excitatory and inhibitory synaptogenesis, and possibly in functional synapse maturation. It has been hypothesized that neurexins and neuroligins are involved in the promiscuous generation of many synapses, before their activity-dependent pruning \[[@B16],[@B66],[@B67]\]. However, multiple neurexin gene knockout studies in mice seem to contradict this and suggest that the neurexin-neuroligin complex is not essential for synapse formation but for synapse function. Deletions of α-Neurexin result in increased lethality, normal synapse number and gross anatomy but severely impaired synaptic functioning, a pattern strikingly similar to neuroligin gene knockouts \[[@B16],[@B66],[@B67]\]. Such biological roles fit with hypotheses of the etiology of autism and schizophrenia in which a neurodevelopmental insult and adult imbalance in excitatory and inhibitory neurotransmission occur in the absence of overt macro-pathology.

*SHANK3*is implicated in autism by several lines of evidence \[[@B23],[@B25],[@B26],[@B68]-[@B70]\] and functions as a post-synaptic scaffolding protein that binds indirectly to neuroligins, forming a potentially functional circuit of neurexin-neuroligin-Shank that is dysregulated in ASDs. The involvement of α-neurexins in pre-synaptic neurotransmission suggests a functional link with voltage-gated calcium channels \[[@B71],[@B72]\], which are integral to pre-synaptic function and plasticity and have been implicated to be involved in autism, schizophrenia and bipolar disorder \[[@B56],[@B58]-[@B60],[@B73]\].

Therefore, the evidence from ASDs, schizophrenia and bipolar disorder suggests a convergence on specific processes involved in the development and regulation of synaptic transmission. Further work on the biology of neurexins, neuroligins and related proteins is certainly required and it seems likely that the pathogenic roles of these proteins will be illuminated by further human genetic studies.

Conclusions
===========

Whole-genome studies of many thousands of affected individuals are uncovering evidence for genetic overlap between autism, schizophrenia and bipolar disorder. Studies of CNVs and other rare alleles have found overlap between autism and schizophrenia, whereas those of common SNP variants have shown overlap between schizophrenia and bipolar disorder. These findings suggest that schizophrenia, autism and other neurodevelopmental disorders may share underlying pathogenic mechanisms and challenges the view that these are completely unrelated diagnostic entities. The findings also support the view that schizophrenia has a stronger neurodevelopmental component than bipolar disorder and suggest that it lies on a gradient of decreasing neurodevelopmental impairment between syndromes such as mental retardation and autism, on one hand, and bipolar disorder on the other \[[@B74]\].

The identification of rare and common alleles predisposing to prototypically distinct psychiatric disorders provides challenges for the ways in which such disorders are diagnosed and researched. We have argued on the basis of recent genetic data that these findings point to common pathophysiological mechanisms, and this is now an important area for future research. We have based this conclusion on the fact that several rare CNVs, including deletions of *NRXN1*, are associated with mental retardation, autism and schizophrenia, and on the overlap in common risk alleles seen between schizophrenia and bipolar disorder \[[@B11]-[@B13]\]. We do not propose that the disorders are the same phenomenologically, and we accept that there may be many genetic and environmental risk factors not shared between the phenotypes.

It is clear that much future work is required and equally clear that this should not be constrained by current categorical diagnostic systems. Such studies should explore the relationship of genes and other biological variables to dimensional measures of key domains of psychopathology across current diagnostic categories. We have previously argued the need to undertake such endeavors across the functional psychoses of schizophrenia and bipolar disorder \[[@B8]\]. However, recent data point to the need to consider a broader clinical spectrum that includes also autism and mental retardation/cognitive impairment \[[@B74]\].
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